Trial Profile
A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Tropisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 28 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Oct 2015 New trial record